Literature DB >> 19755700

Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome.

Marietta Charakida1, Christian Besler, Joana R Batuca, Shirish Sangle, Susanna Marques, Miguel Sousa, Guosu Wang, Dimitris Tousoulis, Jose Delgado Alves, Stavros P Loukogeorgakis, Charles Mackworth-Young, David D'Cruz, Thomas Luscher, Ulf Landmesser, John E Deanfield.   

Abstract

CONTEXT: Accelerated atherosclerosis has been described in antiphospholipid syndrome, but the vascular abnormalities and the underlying mechanisms remain unclear.
OBJECTIVES: To compare vascular structure and function in patients with positive antiphospholipid antibodies (aPL) with controls and to assess their relationship with paraoxonase activity. DESIGN, SETTING, AND PARTICIPANTS: A cross-sectional study of 77 women with positive antiphospholipid antibodies from a lupus outpatient clinic in London, England (90% of the eligible population) and 77 controls matched on frequency basis for age and cardiovascular risk factors between June 2006 and April 2009. Carotid intima media thickness (CIMT), flow-mediated dilatation, pulse wave velocity, and paraoxonase activity were measured in all patients. Anti-inflammatory and antioxidant properties of high-density lipoprotein (HDL) were examined. MAIN OUTCOME MEASURES: CIMT, pulse wave velocity, flow-mediated dilatation, and paraoxonase.
RESULTS: Women with aPL had greater CIMT and pulse wave velocity compared with controls (mean [SD], 0.75 [0.16] vs 0.64 [0.09] mm; 95% confidence interval [CI], -0.14 to -0.06; P < .001; and 9.2 [1.6] vs 8.5 [1.8] m/s; 95% CI, -1.14 to -0.06; P = .04) and lower flow-mediated dilatation (6.2% [4.1%] vs 9.6% [4.2%]; 95% CI, 2.02%-4.69%; P < .001). Paraoxonase activity was lower in women with aPL vs controls (median [interquartile range], 91.2 [64.3-105.1] vs 103.0 [80.5-111.5] micromol p-nitrophenol/L/serum/min; 95% CI, 0.004-0.007; P = .005) and was inversely associated with CIMT and pulse wave velocity in women with aPL (standardized beta coefficient = -0.4 and -0.3, respectively; P < .05 for both), but not in the control group. High-density lipoprotein from women with aPL inhibited endothelial nitric oxide production in human aortic endothelial cells, in contrast with controls. The beneficial effects of HDL from women with aPL on vascular cell adhesion molecule 1 expression, superoxide production, and monocyte adhesion following activation of human aortic endothelial cells were largely blunted.
CONCLUSIONS: Compared with controls, women with aPL had greater functional and structural arterial abnormalities, which were associated with lower activity of paraoxonase. In patients with aPL, HDL reduced nitric oxide bioavailability and had impaired anti-inflammatory and antioxidant properties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19755700     DOI: 10.1001/jama.2009.1346

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  39 in total

Review 1.  Risk factors for venous and arterial thrombosis.

Authors:  Emanuele Previtali; Paolo Bucciarelli; Serena M Passamonti; Ida Martinelli
Journal:  Blood Transfus       Date:  2010-10-25       Impact factor: 3.443

Review 2.  High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease.

Authors:  Meliana Riwanto; Ulf Landmesser
Journal:  J Lipid Res       Date:  2013-07-20       Impact factor: 5.922

Review 3.  The clinical significance of posttranslational modification of autoantigens.

Authors:  Maria G Zavala-Cerna; Erika A Martínez-García; Olivia Torres-Bugarín; Benjamín Rubio-Jurado; Carlos Riebeling; Arnulfo Nava
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 4.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

5.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

6.  Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.

Authors:  Joana R Batuca; Marta C Amaral; Catarina Favas; Filipe S Paula; Paul R J Ames; Ana L Papoila; José Delgado Alves
Journal:  Br J Clin Pharmacol       Date:  2017-01-18       Impact factor: 4.335

Review 7.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

8.  Apolipoprotein a-I at the interface of vascular inflammation and arthritis.

Authors:  Robert Terkeltaub
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-03       Impact factor: 8.311

Review 9.  HDL and endothelial protection.

Authors:  A Tran-Dinh; D Diallo; S Delbosc; L Maria Varela-Perez; Q B Dang; B Lapergue; E Burillo; J B Michel; A Levoye; J L Martin-Ventura; O Meilhac
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Pathophysiological mechanisms in antiphospholipid syndrome.

Authors:  Brock E Harper; Rohan Wills; Silvia S Pierangeli
Journal:  Int J Clin Rheumtol       Date:  2011-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.